AUPH - Aurinia gains 7% on positive Lupkynis data in lupus nephritis study

Aurinia Pharmaceuticals (NASDAQ:AUPH) perks up 6.8% premarket after announcing positive topline results from the AURORA 2 continuation study evaluating the long-term safety and tolerability of Lupkynis (voclosporin) for the treatment of adults with active lupus nephritis (LN), a serious complication in patients with systemic lupus erythematosus. Study demonstrated a favorable risk/benefit profile over a three-year period, with safety comparable to AURORA 1, and sustained efficacy. The mean Urine Protein Creatinine Ratio was lower in the voclosporin-treated groups at all time points during the three years. In the 116 subjects in the voclosporin-treated group, mean estimated glomerular filtration rate (eGFR) was stable over 36 months. Compared to the active control group, the voclosporin-treated group showed an increase from baseline eGFR at the end of the studies of +2.7 mL/min. The drug was well tolerated with no unexpected safety signals observed. Aurinia will host a conference call today at 8:30 am EST to review

For further details see:

Aurinia gains 7% on positive Lupkynis data in lupus nephritis study